Current Consultations

Research Australia regularly contributes to the policy discussions on issues pertinent to Health and Medical Research. This can be through submissions or participating in consultations.

The following lists both consultations and invitations to make submissions which are relevant to health and medical research and/or health and innovation policy in Australia. Research Australia updates this regularly but we may not participate in every one listed.

If you would like more information or you are aware of other consultations that should be included, please contact Greg Mullins, Head of Policy, Research Australia via email greg.mullins@researchaustralia.org or phone (03) 9662 9420.

Please click the heading in the left hand column to access consultation information from the relevant website.

Consultation

Details

R&D Tax Incentive Amendments Senate Inquiry

 

 

On 6 February 2020, the Senate referred the Treasury Laws Amendment (Research and Development Tax Incentive) Bill 2019 to the Economics Legislation Committee for inquiry and report by 30 April 2020. This has now been extended to 7 August because of the impact of COVID-19 on the parliamentary schedule.

The Bill would amend the existing R&DTI scheme to, among other things, introduce a cap on the refundable R&DTI that can be claimed by a company (clinical trials are exempted) and an ‘intensity threshold’ that must be satisfied by larger companies.

Research Australia has made a submission, available here.

Select Committee on COVID-19

 

 

On 8 April 2020, the Senate resolved to establish a Select Committee on COVID-19 to inquire into the Australian Government’s response to the COVID-19 pandemic.

The terms of reference are very broad:

    1. the Australian Government’s response to the COVID-19 pandemic; and
    2. any related matters.

Research Australia has made a submission to the Inquiry, which is available here.

The committee is to present its final report on or before 30 June 2022.